New Study Shows Subglottic Secretions Drainage Reduces Ventilator Associated Pneumonia and Antibiotic Use

View the full release here. Download the study and editorial as pdfs.

The study, which enrolled 714 patients, was conducted by a team led by Emilio Bouza, M.D, PhD, of the Gregorio MaraAon University General Hospital in Madrid, Spain. Cardiac surgery patients were randomized to receive either a standard endotracheal tube or the Hi-Lo Evac(TM) tube to facilitate CASS, also known as subglottic secretions drainage (SSD). Other VAP interventions, such as head of bed elevation and stress-ulcer prophylaxis, were standardized in both groups throughout the duration of the study.

Although subglottic secretions drainage has previously been shown in several studies to reduce VAP, this new study is believed to be the first that has also clearly shown reductions in ICU length of stay and antibiotic usage with the use of CASS.

"In this era of growing concern about antibiotic resistance and the high cost of antibiotics, preventing VAP is clearly preferable to treating it," said Roger Mecca, M.D., Vice President of Medical Affairs for Covidien, manufacturer of the Hi-Lo Evac(TM) endotracheal tube used in the study. "This is one of the first independent studies in the literature that demonstrates not only a reduction in VAP in patients intubated more than 48 hours, but a reduction in antibiotic requirements and duration of mechanical ventilation attributable to the use of CASS."

Key findings of the study include the following:

-- In patients who were mechanically ventilated more than 48 hours, the use of CASS reduced the incidence of VAP by 43 percent.

-- In patients who were mechanically ventilated more than 48 hours, the use of CASS was associated with 9.5 fewer ICU days and four fewer days of mechanical ventilation.

-- In all patients and in those patients who were mechanically ventilated more than 48 hours, CASS was associated with a very significant reduction in the use of antibiotics.

VAP is associated with up to a 27 percent attributable mortality rate and more than $40,000 average increase in hospital cost per incidence.(2,3) Dialogue about "Never Events", public reporting of VAP rates, and possible changes in reimbursement by the Centers for Medicare & Medicaid Services (CMS) have brought increased focus on VAP prevention among care providers and hospital administrators.

"Covidien strongly supports the use of a CASS protocol in patients requiring mechanical ventilation. CASS protocols are recommended in leading infection control guidelines including those from the Centers for Disease Control, the American Thoracic Society, and the Infectious Diseases Society of America," Mecca said. 4,5

A summary of this new study and related studies can be found at http://media.zapvap.com.

COVIDIEN, COVIDIEN with Logo and (TM) marked brands are trademarks of Covidien AG or an affiliate. (C)2008 Covidien. All rights reserved.

About Covidien

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products and Medical Supplies. With 2007 revenue of nearly $9 billion, Covidien has more than 42,000 employees worldwide in 57 countries, and its products are sold in over 130 countries. Please visit www.covidien.com to learn more about our business.

(1) . Bouza E, Jesus Perz M, Munoz P, Rincon C, Barrio JM, Hortal J. Continuous Aspiration of Subglottic Secretions (CASS) in the Prevention of Ventilator Associated Pneumonia in the Postoperative Period of Major Heart Surgery. CHEST; November 2008, 134 (5).

(2) . Fagon JY, Chastre J, et al. Nosocomial Pneumonia in Ventilated Patients: A Cohort Study Evaluating Attributable Mortality and Hospital Stay. The American Journal of Medicine. 1993;94:281-288.

(3) . Rello J, Ollendorf DA, et al. Epidemiology and Outcomes of Ventilator-Associated Pneumonia in a Large US Database. Chest. 2002;122:2115-2121.

(4) . Guidelines for Preventing Healthcare-Associated Pneumonia, 2003, Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. March 26, 2004/53(RR03); 1-36.

(5) . American Journal of Respiratory Critical Care Medicine. 171:388-416.

SOURCE: Covidien

Covidien Terri Black, 303-305-2674 Director, Global Marketing Communications Terri.Black@covidien.com or David Young, 508-261-6330 Manager Media Relations David.Young@covidien.com or Coleman Lannum CFA, 508-452-4343 Vice President Investor Relations Cole.Lannum@covidien.com or Bruce Farmer, 508-452-4372 Vice President Public Relations Bruce.Farmer@covidien.com